Artificial intelligence for cardiovascular disease risk assessment in personalised framework : a scoping review
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Singh, ManasviKumar, Ashish
Khanna, Narendra N
Laird, John R
Nicolaides, Andrew
Faa, Gavino
Johri, A mer M
Mantella, Laura E
Fernandes, Jose F E
Teji, Jagjit S
Singh, Narpinder
Fouda, Mostafa M
Singh, Rajesh
Sharma, Aditya
Kitas, George
Rathore, Vijay
Singh, Inder M
Tadepalli, Kalyan
Al-Maini, Mustafa
Isenovic, Esma R
Chaturvedi, Seemant
Garg, Deepak
Paraskevas, Kosmas I
Mikhailidis, Dimitri P
Viswanathan, Vijay
Kalra, Manudeep K
Ruzsa, Zoltan
Saba, Luca
Laine, Andrew F
Bhatt, Deepak L
Suri, Jasjit S
Affiliation
Bennett University; Indraprastha APOLLO Hospitals; Adventist Health St; University of Nicosia Medical School; The Dudley Group NHS Foundation Trust et alPublication date
07/06/2024Subject
Cardiology
Metadata
Show full item recordAbstract
The field of precision medicine endeavors to transform the healthcare industry by advancing individualised strategies for diagnosis, treatment modalities, and predictive assessments. This is achieved by utilizing extensive multidimensional biological datasets encompassing diverse components, such as an individual's genetic makeup, functional attributes, and environmental influences. Artificial intelligence (AI) systems, namely machine learning (ML) and deep learning (DL), have exhibited remarkable efficacy in predicting the potential occurrence of specific cancers and cardiovascular diseases (CVD). We conducted a comprehensive scoping review guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) framework. Our search strategy involved combining key terms related to CVD and AI using the Boolean operator AND. In August 2023, we conducted an extensive search across reputable scholarly databases including Google Scholar, PubMed, IEEE Xplore, ScienceDirect, Web of Science, and arXiv to gather relevant academic literature on personalised medicine for CVD. Subsequently, in January 2024, we extended our search to include internet search engines such as Google and various CVD websites. These searches were further updated in March 2024. Additionally, we reviewed the reference lists of the final selected research articles to identify any additional relevant literature. Findings: A total of 2307 records were identified during the process of conducting the study, consisting of 564 entries from external sites like arXiv and 1743 records found through database searching. After 430 duplicate articles were eliminated, 1877 items that remained were screened for relevancy. In this stage, 1241 articles remained for additional review after 158 irrelevant articles and 478 articles with insufficient data were removed. 355 articles were eliminated for being inaccessible, 726 for being written in a language other than English, and 281 for not having undergone peer review. Consequently, 121 studies were deemed suitable for inclusion in the qualitative synthesis. At the intersection of CVD, AI, and precision medicine, we found important scientific findings in our scoping review. Intricate pattern extraction from large, complicated genetic datasets is a skill that AI algorithms excel at, allowing for accurate disease diagnosis and CVD risk prediction. Furthermore, these investigations have uncovered unique genetic biomarkers linked to CVD, providing insight into the workings of the disease and possible treatment avenues. The construction of more precise predictive models and personalised treatment plans based on the genetic profiles of individual patients has been made possible by the revolutionary advancement of CVD risk assessment through the integration of AI and genomics. The systematic methodology employed ensured the thorough examination of available literature and the inclusion of relevant studies, contributing to the robustness and reliability of the study's findings. Our analysis stresses a crucial point in terms of the adaptability and versatility of AI solutions. AI algorithms designed in non-CVD domains such as in oncology, often include ideas and tactics that might be modified to address cardiovascular problems.Citation
Singh M, Kumar A, Khanna NN, Laird JR, Nicolaides A, Faa G, Johri AM, Mantella LE, Fernandes JFE, Teji JS, Singh N, Fouda MM, Singh R, Sharma A, Kitas G, Rathore V, Singh IM, Tadepalli K, Al-Maini M, Isenovic ER, Chaturvedi S, Garg D, Paraskevas KI, Mikhailidis DP, Viswanathan V, Kalra MK, Ruzsa Z, Saba L, Laine AF, Bhatt DL, Suri JS. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review. EClinicalMedicine. 2024 May 27;73:102660. doi: 10.1016/j.eclinm.2024.102660PMID
38846068Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.eclinm.2024.102660